February 17, 2021
Blueprint Medicines
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
February 16, 2021
bluebird bio
bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111)
February 16, 2021
Kala Pharmaceuticals
Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts
February 16, 2021
Nurix
Nurix Therapeutics Reports Fourth Quarter And Fiscal Year 2020 Financial Results And Provides A Corporate Update
February 16, 2021
Sesen Bio
Sesen Bio Announces FDA Acceptance and Priority Review of its Biologics License Application for Vicineum™